Dr Pakeeza Sayyed is a Principal Clinical Scientist at F. Hoffmann-La Roche in Basel. She is the lead clinical scientist of the innovative MORPHEUS combinations platform, currently comprising 7 studies. Her key role is to enable and guide effective and efficient execution of the overall MORPHEUS strategy. Prior to MORPHEUS, Pakeeza was working in the Hematology space on various MabThera/Rituxan clinical development studies. She was one of the strategic minds developing and executing the MabThera/Rituxan subcutaneous (SC) program, which was precedent setting for SC formulation development of monoclonal antibodies. Pakeeza is a pharmacist and completed her PhD at Aston University (UK). She joined Baxter Healthcare in Medical Information before moving to Roche, initially in Early R&D as a Study Operational Leader.